ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,605.20
      -1.55%
      US Tech 100
      18,848.80
      -2.16%
      Dow Jones
      41,763.58
      -1.27%
      Brent Oil
      72.535
      -1.17%
      Bitcoin
      83,910.39
      -3.78%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NYSE

      6. Arcus Biosciences Inc (RCUS) Quote

      Arcus Biosciences Inc

      Arcus Biosciences Inc (RCUS)

      NYSE
      8.2359
      -0.2541
      ( -2.99% )
      Updated: 11:56:01
      Delayed by 15 minutes

      Professional-Grade Tools, for Individual Investors.

      Premium

      Key stats and details

      Current Price
      8.2359
      Bid
      -
      Ask
      -
      Volume
      118,492
      8.20 Day's Range 8.57
      8.02 52 Week Range 19.11
      Market Cap
      871.699M
      Previous Close
      8.49
      Open
      8.52
      Last Trade
      1
      @
      8.21
      Last Trade Time
      11:57:48
      Financial Volume
      $ 987,339
      VWAP
      8.3325
      Average Volume (3m)
      925,711
      Shares Outstanding
      105,841,422
      Dividend Yield
      -
      PE Ratio
      -3.10
      Earnings Per Share (EPS)
      -2.67
      Revenue
      258M
      Net Profit
      -283M

      About Arcus Biosciences Inc

      Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule... Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB680, and Zimberelimab. Arcus conducts clinical trials for different types of cancers such as Prostate, Lung, Colorectal, Pancreatic, and others. The company operates through the single segment being the business of developing and commercializing immunotherapies. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.arcusbio.com
      Headquarters
      Camden, Delaware, USA
      Founded
      -
      Arcus Biosciences Inc is listed in the Pharmaceutical Preparations sector of the New York Stock Exchange with ticker RCUS. The last closing price for Arcus Biosciences was $8.49. Over the last year, Arcus Biosciences shares have traded in a share price range of $ 8.02 to $ 19.11.

      Arcus Biosciences currently has 105,841,422 shares outstanding. The market capitalization of Arcus Biosciences is $898.59 million. Arcus Biosciences has a price to earnings ratio (PE ratio) of -3.10.

      Ask ADVFN Intelligence (AI)

      RCUS Latest News

      More News

      Form S-8 - Securities to be offered to employees in employee benefit plans
      Edgar (US Regulatory)
      February 25 2025
      RCUS (-2.99%)

      Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
      Edgar (US Regulatory)
      February 25 2025
      RCUS (-2.99%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      February 25 2025
      RCUS (-2.99%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      February 19 2025
      RCUS (-2.99%)

      Form 424B5 - Prospectus [Rule 424(b)(5)]
      Edgar (US Regulatory)
      February 18 2025
      RCUS (-2.99%)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-0.7041-7.875838926178.949.198.026265548.58698038CS
      4-2.1341-20.579556412710.3711.18.029000809.55091886CS
      12-7.0341-46.064833005915.2715.6158.0292571111.21722881CS
      26-7.1241-46.38085937515.3618.988.0283341913.76433569CS
      52-10.0641-54.995081967218.319.118.0272732014.766409CS
      156-27.7141-77.090681502135.9539.758.0288971919.95532234CS
      260-4.5441-35.556338028212.7849.18.0277891123.28948461CS

      RCUS - Frequently Asked Questions (FAQ)

      What is the current Arcus Biosciences share price?
      The current share price of Arcus Biosciences is $ 8.2359
      How many Arcus Biosciences shares are in issue?
      Arcus Biosciences has 105,841,422 shares in issue
      What is the market cap of Arcus Biosciences?
      The market capitalisation of Arcus Biosciences is USD 898.59M
      What is the 1 year trading range for Arcus Biosciences share price?
      Arcus Biosciences has traded in the range of $ 8.02 to $ 19.11 during the past year
      What is the PE ratio of Arcus Biosciences?
      The price to earnings ratio of Arcus Biosciences is -3.1
      What is the cash to sales ratio of Arcus Biosciences?
      The cash to sales ratio of Arcus Biosciences is 3.4
      What is the reporting currency for Arcus Biosciences?
      Arcus Biosciences reports financial results in USD
      What is the latest annual turnover for Arcus Biosciences?
      The latest annual turnover of Arcus Biosciences is USD 258M
      What is the latest annual profit for Arcus Biosciences?
      The latest annual profit of Arcus Biosciences is USD -283M
      What is the registered address of Arcus Biosciences?
      The registered address for Arcus Biosciences is 2140 S DUPONT HWY, KENT, CAMDEN, DELAWARE, 19934
      What is the Arcus Biosciences website address?
      The website address for Arcus Biosciences is www.arcusbio.com
      Which industry sector does Arcus Biosciences operate in?
      Arcus Biosciences operates in the PHARMACEUTICAL PREPARATIONS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      AGXArgan Inc
      $ 142.22
      (23.42%)
      		743.64k
      SUPPTCW Transform Supply Chain ETF
      $ 66.09
      (12.00%)
      		37
      HMYHarmony Gold Mining Company Limited
      $ 14.0311
      (9.28%)
      		5.61M
      WRBWR Berkley Corp
      $ 71.46
      (7.82%)
      		4.32M
      PERFPerfect Corp
      $ 1.79
      (6.55%)
      		54.55k
      WOLFWolfspeed Inc
      $ 2.76
      (-48.70%)
      		108.3M
      AIRAAR Corp
      $ 59.935
      (-12.31%)
      		676.48k
      CMCMCheetah Mobile Inc
      $ 4.375
      (-9.98%)
      		60.52k
      ANVSAnnovis Bio Inc
      $ 1.675
      (-9.46%)
      		212.5k
      DXYZDestiny Tech100 Inc
      $ 36.52
      (-9.27%)
      		313.08k
      WOLFWolfspeed Inc
      $ 2.76
      (-48.70%)
      		108.3M
      FFord Motor Company
      $ 9.7499
      (-1.52%)
      		66.32M
      NIONIO Inc
      $ 3.80
      (-4.52%)
      		39.67M
      NUNu Holdings Ltd
      $ 10.41
      (-6.13%)
      		29.57M
      GMEGameStop Corp Holding Company
      $ 22.45
      (1.63%)
      		28.3M

      RCUS Discussion

      View Posts
      Monksdream Monksdream 6 months ago
      RCUS a buy under $14
      👍️0
      PennyWorld PennyWorld 2 years ago
      https://seekingalpha.com/news/4005456-roche-send-anti-tigit-developers-higher-after-cancer-drug-data?ref=biztoc.com
      👍️0
      conix conix 3 years ago
      Biotechs are starting to react to news...finally.
      👍️0
      dinogreeves dinogreeves 5 years ago
      The stock didn't react as well as expected with the partnership, but it did hi almost my price target. This is a partnership 200 million equity investment and 175 million up front payment, which. implies no offering on the table. Makes you wonder why the stock is down, guess people were expecting a buyout. Some of these people are so lame, unbelievable.
      👍️0
      lovetc lovetc 5 years ago
      Also in the DEF 14.....didnt see any information regarding Gilead....
      👍️0
      lovetc lovetc 5 years ago
      shorted some and bought some put at $31 last Friday....Also today when it reached $30 I short.....I find no reason not to short above $30 lol....It will be $18 soon since the Volumn start declined....
      👍️0
      dinogreeves dinogreeves 5 years ago
      RCUS will likely hit 40 this week and if it does that could essentially mean that there is buyout looming from GI*LD. Someone is buying heavy between 27-29 dollars, obviously they don't want it dip more than 26-27 dollars, it could be a number of reasons that is beyond any retails control.
      👍️0
      dinogreeves dinogreeves 5 years ago
      Bought another 1000 shares on that dip, going to wait this one.
      👍️0
      dinogreeves dinogreeves 5 years ago
      Possible huge asset buy, or outright buyout coming from GILD or even a partnership.
      👍️0
      dinogreeves dinogreeves 5 years ago
      RCUS getting ready to pop to 33-35 dollars.
      👍️0
      dinogreeves dinogreeves 5 years ago
      This is my letter to the shorts with margin account


      That is where dummies like you are mistaken. If GILD places anywhere close to that dollar amount this stock jumps over triple digits in less then 2 hours and if there is buyout it won't even let you blink, just one share will it to the buyout price. If GOOGLE has 17% stake on this company and GILD is looking to either buy or take a stake, there must be something that you and I are not aware of the current directors sold their pervious company to Bristol for 1.5 billion dollars. There is more here than meets the eye. I am taking my chance because if no balls no glory and when that happens short margin account will be vaporized.


      https://markets.businessinsider.com/news/stocks/arcus-biosciences-stock-spikes-reports-gilead-investing-cancer-drug-biotech-2020-4-1029100118
      👍️0
      dinogreeves dinogreeves 5 years ago
      If this happens the stock will shoot up to over $200 dollars in an instant. Only if that happens.



      https://markets.businessinsider.com/news/stocks/arcus-biosciences-stock-spikes-reports-gilead-investing-cancer-drug-biotech-2020-4-1029100118
      👍️0
      dinogreeves dinogreeves 5 years ago
      News could come from GI*LD that there is a buyout. Watch for news.
      👍️0

      Your Recent History

      NYSE
      RCUS
      Arcus Biosciences
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads